Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) TherapyGlobeNewsWire • 10/10/22
Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer's (SITC) 37th Annual MeetingGlobeNewsWire • 10/05/22
Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum AcceleratesSeeking Alpha • 09/27/22
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced MelanomaGlobeNewsWire • 08/25/22
Iovance Biotherapeutics, Inc. (IOVA) CEO Fred Vogt on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/05/22
Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate UpdatesGlobeNewsWire • 08/04/22
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022GlobeNewsWire • 07/27/22
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meetingMarket Watch • 05/27/22
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced MelanomaGlobeNewsWire • 05/26/22
Iovance Biotherapeutics, Inc. (IOVA) CEO Dr. Fred Vogt on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22
Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate UpdatesGlobeNewsWire • 05/05/22